Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Ionis Pharmaceuticals Inc (NASDAQ: IONS) closed at $72.67 up 0.30% from its previous closing price of $72.45. In other words, the price has increased by $0.30 from its previous closing price. On the day, 5.05 million shares were traded. IONS stock price reached its highest trading level at $74.5 during the session, while it also had its lowest trading level at $70.4.
Ratios:
For a deeper understanding of Ionis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 3.32 whereas as Long-Term Debt/Eq ratio is at 2.27.
On September 26, 2025, Goldman Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $65.
BMO Capital Markets Upgraded its Market Perform to Outperform on September 03, 2025, while the target price for the stock was maintained at $70.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 06 ’25 when Birchler Brian sold 8,000 shares for $76.17 per share. The transaction valued at 609,379 led to the insider holds 48,826 shares of the business.
Geary Richard S sold 33,038 shares of IONS for $2,501,725 on Nov 06 ’25. The EVP, Chief Development Officer now owns 59,657 shares after completing the transaction at $75.72 per share. On Nov 05 ’25, another insider, Geary Richard S, who serves as the EVP, Chief Development Officer of the company, sold 1,601 shares for $75.01 each. As a result, the insider received 120,091 and left with 59,657 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IONS now has a Market Capitalization of 11770679296 and an Enterprise Value of 11586727936. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.17 while its Price-to-Book (P/B) ratio in mrq is 18.95. Its current Enterprise Value per Revenue stands at 11.983 whereas that against EBITDA is -43.429.
Stock Price History:
The Beta on a monthly basis for IONS is 0.31, which has changed by 0.9460113 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, IONS has reached a high of $76.78, while it has fallen to a 52-week low of $23.95. The 50-Day Moving Average of the stock is 6.57%, while the 200-Day Moving Average is calculated to be 65.78%.
Shares Statistics:
For the past three months, IONS has traded an average of 2.51M shares per day and 2472360 over the past ten days. A total of 161.14M shares are outstanding, with a floating share count of 160.80M. Insiders hold about 0.72% of the company’s shares, while institutions hold 104.69% stake in the company. Shares short for IONS as of 1761868800 were 12661274 with a Short Ratio of 5.05, compared to 1759190400 on 12278792. Therefore, it implies a Short% of Shares Outstanding of 12661274 and a Short% of Float of 10.319999600000001.
Earnings Estimates
Ionis Pharmaceuticals Inc (IONS) is currently under the scrutiny of 8.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.34 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$1.2 and -$2.35 for the fiscal current year, implying an average EPS of -$1.67. EPS for the following year is -$2.2, with 12.0 analysts recommending between -$1.08 and -$3.73.
Revenue Estimates
A total of 14 analysts believe the company’s revenue will be $151.28M this quarter.It ranges from a high estimate of $170M to a low estimate of $125M. As of. The current estimate, Ionis Pharmaceuticals Inc’s year-ago sales were $227MFor the next quarter, 14 analysts are estimating revenue of $188.91M. There is a high estimate of $242M for the next quarter, whereas the lowest estimate is $145.53M.
A total of 20 analysts have provided revenue estimates for IONS’s current fiscal year. The highest revenue estimate was $922.7M, while the lowest revenue estimate was $865M, resulting in an average revenue estimate of $895.26M. In the same quarter a year ago, actual revenue was $705MBased on 22 analysts’ estimates, the company’s revenue will be $924.04M in the next fiscal year. The high estimate is $1.15B and the low estimate is $681.53M.
